{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T15:53:14Z","timestamp":1792511594428,"version":"4.5.0"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,3,10]],"date-time":"2021-03-10T00:00:00Z","timestamp":1615334400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2021,3,10]],"date-time":"2021-03-10T00:00:00Z","timestamp":1615334400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000069","name":"National Institute of Arthritis and Musculoskeletal and Skin Diseases","doi-asserted-by":"publisher","award":["2P50AR065139-05"],"award-info":[{"award-number":["2P50AR065139-05"]}],"id":[{"id":"10.13039\/100000069","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012644","name":"Friends of FSH Research","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100012644","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Musculoskelet Disord"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Facioscapulohumeral muscular dystrophy (FSHD) is a patchy and slowly progressive disease of skeletal muscle. For MRI to be a useful biomarker in an FSHD clinical trial, it should reliably detect changes over relatively short time-intervals (~\u20091\u2009year). We hypothesized that fatty change over the study course would be most likely in muscles already demonstrating disease progression, and that the degree of MRI burden would be correlated with function.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We studied 36 patients with FSHD and lower-extremity weakness at baseline. Thirty-two patients returned in our 12-month longitudinal observational study. We analyzed DIXON MRI images of 16 lower-extremity muscles in each patient and compared them to quantitative strength measurement and ambulatory functional outcome measures.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>There was a small shift to higher fat fractions in the summed muscle data for each patient, however individual muscles demonstrated much larger magnitudes of change. The greatest increase in fat fraction was observed in muscles having an intermediate fat replacement at baseline, with minimally (baseline fat fraction &lt;\u20090.10) or severely (&gt;\u20090.70) affected muscles less likely to progress. Functional outcome measures did not demonstrate marked change over the interval; however, overall MRI disease burden was correlated with functional outcome measures. Direct comparison of the tibialis anterior (TA) fat fraction and quantitative strength measurement showed a sigmoidal relationship, with steepest drop being when the muscle gets more than\u00a0~\u200920% fatty replaced.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Assessing MRI changes in 16 lower-extremity muscles across 1 year demonstrated that those muscles having an intermediate baseline fat fraction were more likely to progress. Ambulatory functional outcome measures are generally related to overall muscle MRI burden but remain unchanged in the short term. Quantitative strength measurement of the TA showed a steep loss of strength when more fatty infiltration is present suggesting that MRI may be preferable for following incremental change or modulation with drug therapy.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12891-021-04134-7","type":"journal-article","created":{"date-parts":[[2021,3,10]],"date-time":"2021-03-10T17:05:18Z","timestamp":1615395918000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":51,"title":["Longitudinal study of MRI and functional outcome measures in facioscapulohumeral muscular dystrophy"],"prefix":"10.1186","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5079-1416","authenticated-orcid":false,"given":"Leo H.","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dennis W. W.","family":"Shaw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Faino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher B.","family":"Budech","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leann M.","family":"Lewis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey","family":"Statland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katy","family":"Eichinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen J.","family":"Tapscott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rabi N.","family":"Tawil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seth D.","family":"Friedman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,3,10]]},"reference":[{"issue":"3","key":"4134_CR1","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1007\/s00415-016-8361-3","volume":"264","author":"G Andersen","year":"2017","unstructured":"Andersen G, Dahlqvist JR, Vissing CR, Heje K, Thomsen C, Vissing J. MRI as outcome measure in facioscapulohumeral muscular dystrophy: 1-year follow-up of 45 patients. J Neurol. 2017;264(3):438\u201347. https:\/\/doi.org\/10.1007\/s00415-016-8361-3.","journal-title":"J Neurol"},{"issue":"8","key":"4134_CR2","doi-asserted-by":"publisher","first-page":"e0183825","DOI":"10.1371\/journal.pone.0183825","volume":"12","author":"F Fatehi","year":"2017","unstructured":"Fatehi F, Salort-Campana E, Le Troter A, Lareau-Trudel E, Bydder M, Foure A, et al. Long-term follow-up of MRI changes in thigh muscles of patients with Facioscapulohumeral dystrophy: A quantitative study. PLoS One. 2017;12(8):e0183825. https:\/\/doi.org\/10.1371\/journal.pone.0183825.","journal-title":"PLoS One"},{"issue":"6","key":"4134_CR3","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1002\/mus.26038","volume":"57","author":"MR Ferguson","year":"2018","unstructured":"Ferguson MR, Poliachik SL, Budech CB, Gove NE, Carter GT, Wang LH, et al. MRI change metrics of facioscapulohumeral muscular dystrophy: Stir and T1. Muscle Nerve. 2018;57(6):905\u201312. https:\/\/doi.org\/10.1002\/mus.26038.","journal-title":"Muscle Nerve"},{"key":"4134_CR4","doi-asserted-by":"publisher","unstructured":"Dahlqvist JR, Poulsen NS, Ostergaard ST, Fornander F, de Stricker BJ, Danielsen ER, et al. Evaluation of inflammatory lesions over 2 years in facioscapulohumeral muscular dystrophy. Neurology. 2020. https:\/\/doi.org\/10.1212\/WNL.0000000000010155.","DOI":"10.1212\/WNL.0000000000010155"},{"issue":"5","key":"4134_CR5","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1007\/s00415-019-09242-y","volume":"266","author":"JR Dahlqvist","year":"2019","unstructured":"Dahlqvist JR, Andersen G, Khawajazada T, Vissing C, Thomsen C, Vissing J. Relationship between muscle inflammation and fat replacement assessed by MRI in facioscapulohumeral muscular dystrophy. J Neurol. 2019;266(5):1127\u201335. https:\/\/doi.org\/10.1007\/s00415-019-09242-y.","journal-title":"J Neurol"},{"issue":"2","key":"4134_CR6","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1002\/mus.23911","volume":"49","author":"SD Friedman","year":"2014","unstructured":"Friedman SD, Poliachik SL, Otto RK, Carter GT, Budech CB, Bird TD, et al. Longitudinal features of STIR bright signal in FSHD. Muscle Nerve. 2014;49(2):257\u201360. https:\/\/doi.org\/10.1002\/mus.23911.","journal-title":"Muscle Nerve"},{"issue":"1","key":"4134_CR7","doi-asserted-by":"publisher","first-page":"e85416","DOI":"10.1371\/journal.pone.0085416","volume":"9","author":"BH Janssen","year":"2014","unstructured":"Janssen BH, Voet NB, Nabuurs CI, Kan HE, de Rooy JW, Geurts AC, et al. Distinct disease phases in muscles of facioscapulohumeral dystrophy patients identified by MR detected fat infiltration. PLoS One. 2014;9(1):e85416. https:\/\/doi.org\/10.1371\/journal.pone.0085416.","journal-title":"PLoS One"},{"issue":"6","key":"4134_CR8","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1002\/1531-8249(199906)45:6<751::AID-ANA9>3.0.CO;2-M","volume":"45","author":"E Ricci","year":"1999","unstructured":"Ricci E, Galluzzi G, Deidda G, Cacurri S, Colantoni L, Merico B, et al. Progress in the molecular diagnosis of facioscapulohumeral muscular dystrophy and correlation between the number of KpnI repeats at the 4q35 locus and clinical phenotype. Ann Neurol. 1999;45(6):751\u20137.","journal-title":"Ann Neurol"},{"issue":"3 Pt 1","key":"4134_CR9","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1212\/wnl.44.3_part_1.442","volume":"44","author":"R Tawil","year":"1994","unstructured":"Tawil R, McDermott MP, Mendell JR, Kissel J, Griggs RC. Facioscapulohumeral muscular dystrophy (FSHD): design of natural history study and results of baseline testing. FSH-DY Group. Neurology. 1994;44(3 Pt 1):442\u20136. https:\/\/doi.org\/10.1212\/wnl.44.3_part_1.442.","journal-title":"Neurology"},{"issue":"3","key":"4134_CR10","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1093\/hmg\/ddy364","volume":"28","author":"LH Wang","year":"2019","unstructured":"Wang LH, Friedman SD, Shaw D, Snider L, Wong CJ, Budech CB, et al. MRI-informed muscle biopsies correlate MRI with pathology and DUX4 target gene expression in FSHD. Hum Mol Genet. 2019;28(3):476\u201386. https:\/\/doi.org\/10.1093\/hmg\/ddy364.","journal-title":"Hum Mol Genet"},{"issue":"6","key":"4134_CR11","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.1093\/hmg\/ddaa031","volume":"29","author":"CJ Wong","year":"2020","unstructured":"Wong CJ, Wang LH, Friedman SD, Shaw D, Campbell AE, Budech CB, et al. Longitudinal measures of RNA expression and disease activity in FSHD muscle biopsies. Hum Mol Genet. 2020;29(6):1030\u201343. https:\/\/doi.org\/10.1093\/hmg\/ddaa031.","journal-title":"Hum Mol Genet"},{"issue":"20","key":"4134_CR12","doi-asserted-by":"publisher","first-page":"2057","DOI":"10.1212\/WNL.0000000000004647","volume":"89","author":"K Mul","year":"2017","unstructured":"Mul K, Vincenten SCC, Voermans NC, Lemmers R, van der Vliet PJ, van der Maarel SM, et al. Adding quantitative muscle MRI to the FSHD clinical trial toolbox. Neurology. 2017;89(20):2057\u201365. https:\/\/doi.org\/10.1212\/WNL.0000000000004647.","journal-title":"Neurology"},{"issue":"4","key":"4134_CR13","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1002\/mus.24569","volume":"52","author":"DG Leung","year":"2015","unstructured":"Leung DG, Carrino JA, Wagner KR, Jacobs MA. Whole-body magnetic resonance imaging evaluation of facioscapulohumeral muscular dystrophy. Muscle Nerve. 2015;52(4):512\u201320. https:\/\/doi.org\/10.1002\/mus.24569.","journal-title":"Muscle Nerve"},{"issue":"11","key":"4134_CR14","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1007\/s00415-006-0230-z","volume":"253","author":"DB Olsen","year":"2006","unstructured":"Olsen DB, Gideon P, Jeppesen TD, Vissing J. Leg muscle involvement in facioscapulohumeral muscular dystrophy assessed by MRI. J Neurol. 2006;253(11):1437\u201341. https:\/\/doi.org\/10.1007\/s00415-006-0230-z.","journal-title":"J Neurol"},{"issue":"13","key":"4134_CR15","doi-asserted-by":"publisher","first-page":"e1386","DOI":"10.1212\/WNL.0000000000008939","volume":"94","author":"KJ Naarding","year":"2020","unstructured":"Naarding KJ, Reyngoudt H, van Zwet EW, Hooijmans MT, Tian C, Rybalsky I, et al. MRI vastus lateralis fat fraction predicts loss of ambulation in Duchenne muscular dystrophy. Neurology. 2020;94(13):e1386\u2013e94. https:\/\/doi.org\/10.1212\/WNL.0000000000008939.","journal-title":"Neurology"},{"issue":"15","key":"4134_CR16","doi-asserted-by":"publisher","first-page":"e1622","DOI":"10.1212\/WNL.0000000000009244","volume":"94","author":"WD Rooney","year":"2020","unstructured":"Rooney WD, Berlow YA, Triplett WT, Forbes SC, Willcocks RJ, Wang DJ, et al. Modeling disease trajectory in Duchenne muscular dystrophy. Neurology. 2020;94(15):e1622\u2013e33. https:\/\/doi.org\/10.1212\/WNL.0000000000009244.","journal-title":"Neurology"},{"issue":"3","key":"4134_CR17","doi-asserted-by":"publisher","first-page":"e0194283","DOI":"10.1371\/journal.pone.0194283","volume":"13","author":"AM Barnard","year":"2018","unstructured":"Barnard AM, Willcocks RJ, Finanger EL, Daniels MJ, Triplett WT, Rooney WD, et al. Skeletal muscle magnetic resonance biomarkers correlate with function and sentinel events in Duchenne muscular dystrophy. PLoS One. 2018;13(3):e0194283. https:\/\/doi.org\/10.1371\/journal.pone.0194283.","journal-title":"PLoS One"},{"issue":"3","key":"4134_CR18","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1148\/radiol.2020192210","volume":"295","author":"SC Forbes","year":"2020","unstructured":"Forbes SC, Arora H, Willcocks RJ, Triplett WT, Rooney WD, Barnard AM, et al. Upper and lower extremities in duchenne muscular dystrophy evaluated with quantitative mri and proton mr spectroscopy in a multicenter cohort. Radiology. 2020;295(3):616\u201325. https:\/\/doi.org\/10.1148\/radiol.2020192210.","journal-title":"Radiology"},{"issue":"5","key":"4134_CR19","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1016\/j.nmd.2009.02.009","volume":"19","author":"HE Kan","year":"2009","unstructured":"Kan HE, Scheenen TW, Wohlgemuth M, Klomp DW, van Loosbroek-Wagenmans I, Padberg GW, et al. Quantitative MR imaging of individual muscle involvement in facioscapulohumeral muscular dystrophy. Neuromuscul Disord. 2009;19(5):357\u201362. https:\/\/doi.org\/10.1016\/j.nmd.2009.02.009.","journal-title":"Neuromuscul Disord"},{"issue":"1","key":"4134_CR20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3233\/JND-160145","volume":"3","author":"PG Carlier","year":"2016","unstructured":"Carlier PG, Marty B, Scheidegger O, Loureiro de Sousa P, Baudin PY, Snezhko E, et al. Skeletal muscle quantitative nuclear magnetic resonance imaging and spectroscopy as an outcome measure for clinical trials. J Neuromuscul Dis. 2016;3(1):1\u201328. https:\/\/doi.org\/10.3233\/JND-160145.","journal-title":"J Neuromuscul Dis"}],"container-title":["BMC Musculoskeletal Disorders"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12891-021-04134-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12891-021-04134-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12891-021-04134-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,10]],"date-time":"2021-03-10T17:05:22Z","timestamp":1615395922000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcmusculoskeletdisord.biomedcentral.com\/articles\/10.1186\/s12891-021-04134-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,10]]},"references-count":20,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["4134"],"URL":"https:\/\/doi.org\/10.1186\/s12891-021-04134-7","relation":{},"ISSN":["1471-2474"],"issn-type":[{"value":"1471-2474","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,10]]},"assertion":[{"value":"23 July 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 March 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 March 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the Human Subjects Committee at Universities of Rochester and Washington, with written informed consent obtained for all participants.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"This was part of the informed consent.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"LHW reports consultancy for Biogen. KE reports consultancy for Fulcrum Therapeutics, Acceleron, Biogen, and Ionis. SDF and SJT report consultancy for Fulcrum Therapeutics. RT reports consultancy with Fulcrum Therapeutics and Acceleron Pharma. JS reports consultancy for Fulcrum Therapeutics, Acceleron, Strongbridge Biopharma, AveXis, Sarepta, PTC, and Expansion.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"262"}}